NICE announce positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO
College Statement In response to NICE announcing their positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea® (aflibercept) as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
UK Vision Strategy eye health and sight loss statistics report for England
In February 2014 the UK Vision Strategy Partnership launched an eye health and sight loss statistics report for England.The report brings together data for England on all aspects of eye health and sight loss including: The rate of Certification of Vision Impairment The numbers registered with sight loss or severe sight loss Sight tests Outpatient
Class 2 Medicines Recall (action within 48 hours): COSOPT Preservative-Free, 20mg/ml +5mg/ml, eye drops, solution, single-dose container – Merck Sharp & Dohme Limited (EL (14)A/02)
Merck Sharp & Dohme Limited COSOPT Preservative-Free, 20mg/ml +5mg/ml, eye drops, solution, single-dose container (Dorzolamide / Timolol) PL 00025/0698 Batch number Expiry Date Pack size First distributed MK13D002 30 April 2015 60 single dose containers 9 September 2013 MK13D004 30 April 2015 60 single dose containers 4 July 2013 Merck Sharp and Dohme is recalling
Survey results show under resourced eye clinics put patients’ sight at risk
Press Release UK survey by the Macular Society and the Royal College of Ophthalmologists highlights concerns over eye clinic capacity Thousands of elderly people with eye disease are receiving poor or very poor NHS services according to a survey of hospital ophthalmologists. The survey, by the Macular Society and the Royal College of Ophthalmologists, asked
UK National Screening Committee policy on Vision defects screening in children
College Statement The Royal College of Ophthalmologists supports the recommendation of the National Screening Committee that screening for visual impairment in children, between the ages of 4 and 5 years, should be offered by an orthoptic-led service.http://www.screening.nhs.uk/vision-child The College strongly advocates early screening for the detection of visual problems and eye disorders in children at